

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of )  
 )  
Christer NORDSTEDT et al. ) Group Art Unit: Unassigned  
 )  
Serial No.: Unassigned ) Examiner: Unassigned  
 )  
Filed: May 8, 2001 )  
 )  
For: PEPTIDE BINDING KLVFF- )  
SEQUENCE OF AMYLOID BETA )

**DECLARATION PURSUANT TO**  
**37 C.F.R. §§1.821-1.825**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

I, Mercedes K. Meyer, declare as follows:


1. That the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same in compliance with §1.821(f).
2. That the submission, filed in accordance with 37 C.F.R. §1.821(g)[or (h)], herein does not include new matter or go beyond the disclosure in the international application or in corresponding U.S. Serial No. 09/095,106.
3. That the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(d), is identical to that originally filed in U.S. Serial No. 09/095,106.

Serial No.: Unassigned

I hereby declare that all statements made herein of my own knowledge are true and that all statements were made on information and belief and are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

May 8, 2001

Date

  
Mercedes K. Meyer  
Registration No. 44,939

# SEQUENCE LISTING

<110> NORDSTEDT, Christer  
 NASLUND, Jan  
 THYBERG, Johan  
 TJERNBERG, Lars O.  
 TERNENIUS, Lars

<120> PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID-BETA

<130> 000500-124

<140> 09/095,106

<141> 1998-06-10

<150> US 60/009,386

<151> 1995-12-29

<150> PCT/SE96/01621

<151> 1996-12-09

<160> 44

<170> PatentIn Ver. 2.0

<210> 1

<211> 5

<212> PRT

<213> Amyloidosis

<400> 1

Lys Leu Val Phe Phe  
 1 5

<210> 2

<211> 10

<212> PRT

<213> Amyloidosis

<400> 2

Glu Val His His Gln Lys Leu Val Phe Phe  
 1 5 10

<210> 3

<211> 5

<212> PRT

<213> Amyloidosis

<220>

<221> PEPTIDE

<222> (3)..(4)

<223> Amino acids 3 and 4 are Xaa wherein Xaa = any  
 group or amino acid.

<400> 3

Lys Leu Xaa Xaa Phe

1

5

<210> 4  
<211> 5  
<212> PRT  
<213> Amyloidosis

<400> 4  
Ala Ala Val Phe Ala  
1 5

<210> 5  
<211> 6  
<212> PRT  
<213> Amyloidosis

<400> 5  
Gln Lys Leu Val Phe Phe  
1 5

<210> 6  
<211> 9  
<212> PRT  
<213> Amyloidosis

<400> 6  
Val His His Gln Lys Leu Val Phe Phe  
1 5

<210> 7  
<211> 9  
<212> PRT  
<213> Amyloidosis

<400> 7  
Glu Val His His Gln Lys Leu Val Phe  
1 5

<210> 8  
<211> 8  
<212> PRT  
<213> Amyloidosis

<400> 8  
His His Gln Lys Leu Val Phe Phe  
1 5

<210> 9  
<211> 8  
<212> PRT  
<213> Amyloidosis

<400> 9

Val His His Gln Lys Leu Val Phe  
1 5

<210> 10  
<211> 8  
<212> PRT  
<213> Amyloidosis

<400> 10  
Glu Val His His Gln Lys Leu Val  
1 5

<210> 11  
<211> 7  
<212> PRT  
<213> Amyloidosis

<400> 11  
His Gln Lys Leu Val Phe Phe  
1 5

<210> 12  
<211> 7  
<212> PRT  
<213> Amyloidosis

<400> 12  
His His Gln Lys Leu Val Phe  
1 5

<210> 13  
<211> 7  
<212> PRT  
<213> Amyloidosis

<400> 13  
Val His His Gln Lys Leu Val  
1 5

<210> 14  
<211> 7  
<212> PRT  
<213> Amyloidosis

<400> 14  
Glu Val His His Gln Lys Leu  
1 5

<210> 15  
<211> 6  
<212> PRT  
<213> Amyloidosis

<400> 15  
His Gln Lys Leu Val Phe  
1 5

<210> 16  
<211> 6  
<212> PRT  
<213> Amyloidosis

<400> 16  
His His Gln Lys Leu Val  
1 5

<210> 17  
<211> 6  
<212> PRT  
<213> Amyloidosis

<400> 17  
Val His His Gln Lys Leu  
1 5

<210> 18  
<211> 6  
<212> PRT  
<213> Amyloidosis

<400> 18  
Glu Val His His Gln Lys  
1 5

<210> 19  
<211> 5  
<212> PRT  
<213> Amyloidosis

<400> 19  
Gln Lys Leu Val Phe  
1 5

<210> 20  
<211> 5  
<212> PRT  
<213> Amyloidosis

<400> 20  
His Gln Lys Leu Val  
1 5

<210> 21  
<211> 5  
<212> PRT  
<213> Amyloidosis

<400> 21  
His His Gln Lys Leu  
1 5

<210> 22  
<211> 5  
<212> PRT  
<213> Amyloidosis

<400> 22  
Val His His Gln Lys  
1 5

<210> 23  
<211> 5  
<212> PRT  
<213> Amyloidosis

<400> 23  
Glu Val His His Gln  
1 5

<210> 24  
<211> 4  
<212> PRT  
<213> Amyloidosis

<400> 24  
Leu Val Phe Phe  
1

<210> 25  
<211> 4  
<212> PRT  
<213> Amyloidosis

<400> 25  
Lys Leu Val Phe  
1

<210> 26  
<211> 4  
<212> PRT  
<213> Amyloidosis

<400> 26  
Gln Lys Leu Val  
1

<210> 27  
<211> 4  
<212> PRT  
<213> Amyloidosis

<400> 27  
His Gln Lys Leu  
1

<210> 28  
<211> 4  
<212> PRT  
<213> Amyloidosis

<400> 28  
His His Gln Lys  
1

<210> 29  
<211> 4  
<212> PRT  
<213> Amyloidosis

<400> 29  
Val His His Gln  
1

<210> 30  
<211> 4  
<212> PRT  
<213> Amyloidosis

<400> 30  
Glu Val His His  
1

<210> 31  
<211> 3  
<212> PRT  
<213> Amyloidosis

<400> 31  
Val Phe Phe  
1

<210> 32  
<211> 3  
<212> PRT  
<213> Amyloidosis

<400> 32  
Leu Val Phe  
1

<210> 33  
<211> 3  
<212> PRT  
<213> Amyloidosis



<400> 33  
Lys Leu Val  
1

<210> 34  
<211> 3  
<212> PRT  
<213> Amyloidosis

<400> 34  
Gln Lys Leu  
1

<210> 35  
<211> 3  
<212> PRT  
<213> Amyloidosis

<400> 35  
His Gln Lys  
1

<210> 36  
<211> 3  
<212> PRT  
<213> Amyloidosis

<400> 36  
His His Gln  
1

<210> 37  
<211> 3  
<212> PRT  
<213> Amyloidosis

<400> 37  
Val His His  
1

<210> 38  
<211> 3  
<212> PRT  
<213> Amyloidosis

<400> 38  
Glu Val His  
1

<210> 39  
<211> 5  
<212> PRT  
<213> Amyloidosis

<400> 39  
Ala Leu Val Phe Phe  
1 5

<210> 40  
<211> 5  
<212> PRT  
<213> Amyloidosis

<400> 40  
Lys Ala Val Phe Phe  
1 5

<210> 41  
<211> 5  
<212> PRT  
<213> Amyloidosis

<400> 41  
Lys Leu Ala Phe Phe  
1 5

<210> 42  
<211> 5  
<212> PRT  
<213> Amyloidosis

<400> 42  
Lys Leu Val Ala Phe  
1 5

<210> 43  
<211> 5  
<212> PRT  
<213> Amyloidosis

<400> 43  
Lys Leu Val Phe Ala  
1 5

<210> 44  
<211> 8  
<212> PRT  
<213> Amyloidosis

<400> 44  
Lys Leu Val Phe Phe Ala Ala Cys  
1 5